Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canerpaturev - Takara Bio

Drug Profile

Canerpaturev - Takara Bio

Alternative Names: C-REV; HF-10; Msc-2; TBI-1401

Latest Information Update: 28 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ms Science; Nagoya University
  • Developer Takara Bio; University of Utah
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • No development reported Head and neck cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (Intratumoural, Injection)
  • 09 Nov 2021 Otsuka Pharmaceutical terminates licensing agreement with Takara Bio for Canerpaturev in Japan
  • 20 Jan 2021 Canerpaturev is still in phase I trial for Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (Otsuka Pharmaceuticals pipeline, January 2021) (NCT03252808)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top